96X Stock Overview
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
FluoGuide A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr3.60 |
| 52 Week High | kr9.88 |
| 52 Week Low | kr3.47 |
| Beta | 1.07 |
| 1 Month Change | -15.41% |
| 3 Month Change | -33.92% |
| 1 Year Change | -47.59% |
| 3 Year Change | -65.96% |
| 5 Year Change | n/a |
| Change since IPO | -74.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 96X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -4.3% | -2.5% |
| 1Y | -47.6% | -19.4% | -0.4% |
Return vs Industry: 96X underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 96X underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 96X volatility | |
|---|---|
| 96X Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 96X's share price has been volatile over the past 3 months.
Volatility Over Time: 96X's weekly volatility has decreased from 13% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 8 | Morten Albrechtsen | fluoguide.com |
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology.
FluoGuide A/S Fundamentals Summary
| 96X fundamental statistics | |
|---|---|
| Market cap | €46.71m |
| Earnings (TTM) | -€5.14m |
| Revenue (TTM) | €56.69k |
824.0x
P/S Ratio-9.1x
P/E RatioIs 96X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 96X income statement (TTM) | |
|---|---|
| Revenue | kr.423.00k |
| Cost of Revenue | kr.0 |
| Gross Profit | kr.423.00k |
| Other Expenses | kr.38.80m |
| Earnings | -kr.38.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -3.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | -9,072.58% |
| Debt/Equity Ratio | 78.6% |
How did 96X perform over the long term?
See historical performance and comparison